Evaluate Launches Enhanced Orphan Drug Intelligence

London And Boston (ots/PRNewswire) -

The worldwide orphan drug market is set to reach $127 billion by
2018, accounting for nearly 16 percent of total prescription drug
sales, according to the recently released Orphan Drug Report 2013
[http://www.evaluategroup.com/orphandrug2013 ] from Evaluate
[http://www.evaluategroup.com ].

To better serve its clients' needs in regard to this growing segment
of the pharmaceutical industry, Evaluate has enhanced its
EvaluatePharma
[http://www.evaluategroup.com/public/EvaluatePharma-Overview.aspx ]
core product database to include in-depth, fact-based orphan drug
analysis with data fields for integrated US, EU and Japan orphan drug
designations. The enhanced orphan drug content will be available to
all EvaluatePharma service clients on June 20, 2013.

"As a company, we are focused on our clients' success. This
enhancement allows our clients to size and track the orphan drug
market in order to make more informed, strategic decisions about
portfolio strategy, growth opportunities and investments," said
Anthony Raeside, Head of Research at Evaluate.

EvaluatePharma has identified all products that have orphan drug
designations filed in the US, EU or Japan, and has defined a clean
'orphan' sub-set of products through a fully transparent and
documented methodology.

The new enhancement facilitates global analysis of the orphan drug
R&D and commercial landscape - including the ability to:

- TRACK the orphan drug market via a transparent methodology
- MAKE orphan drug commercial assessments
- CONDUCT competitive intelligence including patent expiries and 
exclusivities
- SCREEN for orphan drug licensing opportunities by product, 
designation,
  indication
- BENCHMARK current and historical orphan drug deal terms and values
- IDENTIFY the future value of an orphan drug market via consensus 
sales
  forecasts
- KNOW the latest news and orphan drug designations and approvals

For more information on the EvaluatePharma service, please visit
http://www.evaluategroup.com. The complimentary Orphan Drug 2013
report is available for download at
http://www.evaluategroup.com/orphandrug2013.

If you are attending the 2013 DIA Annual Meeting
[http://www.diahome.org/en/Flagship-Meetings/DIA2013.aspx ] or the
EphMRA 2013 [http://www.ephmra2013.org ] conference and would like to
meet, please contact us [http://www.evaluategroup.com/Enquiry.aspx ].

About Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality life
science sector analysis. EvaluatePharma
[http://www.evaluatepharma.com ] delivers exclusive consensus sales
forecasts and trusted commercial insight into biotech and
pharmaceutical performance. EvaluateMedTech
[http://www.evaluatemedtech.com ] sets a new standard in integrated
analysis and consensus forecasts of the global medical device and
diagnostic industry. EvaluateClinical Trials [http://www.evaluategro
up.com/public/EvaluateClinicalTrials-Overview.aspx ] delivers unique
intelligence to efficiently and accurately analyze the global
clinical trial landscape. A team of more than 85 dedicated healthcare
analysts employ rigorous methodologies to collate, organize and
deliver the most-up-to-date commercial performance data available. An
award-winning editorial team of journalists writing under the EP
Vantage name support EvaluatePharma's analysis. The Evaluate services
enable the life science community to make sound business decisions
about value and opportunity. For more information please visit
http://www.evaluategroup.com. On Twitter: @evaluatepharma
[https://twitter.com/evaluatepharma ], @evaluatemedtech
[https://twitter.com/EvaluateMedTech ], @epclinicaltrial
[https://twitter.com/EPClinicalTrial ], @epvantage
[https://twitter.com/EPVantage ].

Media Contacts:
Evaluate and EP Vantage
Christine Lindgren
+1-617-866-3906
christine.lindgren@evaluategroup.com

Chempetitive Group (for US media)
Rachel Lear
+1-781-775-3640
rlear@chempetitive.com

College Hill (for non-US media)
Melanie Toyne Sewell / Stephanie Bacher / Gemma Howe
+44(0)20-7457-2020
evaluate@collegehill.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print